Insights

Immuno-oncology Focus SparX Biopharmaceutical Corp specializes in strengthening human immunity through innovative immuno-oncology agents, presenting a compelling opportunity for collaboration on antibody therapies and combination regimens.

Target Discovery Platform Advancements in their multi-component target discovery platform and SAILING antibody optimization system suggest potential in joint development or licensing discussions around novel targets and best-in-class antibody drugs.

In-house cGMP Capability Built-in manufacturing capacity for clinical and commercial products enables end-to-end partnerships and reduced third-party risks, appealing to collaborators seeking integrated development pipelines.

Phase 1 Updates Active clinical progress with SPX-303, a dual checkpoint bispecific antibody, and upcoming Phase 1 data presentation at AACR 2025 indicates near-term collaboration windows for co-development, strategy alignment, or licensing opportunities.

Funding Signals Estimated revenue range positions SparX as a mid-scale partner with growth potential, suggesting suitability for strategic alliances, milestone-driven collaborations, and investment-led partnering discussions.

SPARX BIOPHARMACEUTICAL CORP Tech Stack

SPARX BIOPHARMACEUTICAL CORP uses 8 technology products and services including RSS, WordPress, 1&1, and more. Explore SPARX BIOPHARMACEUTICAL CORP's tech stack below.

RSS

Content Management System

WordPress

Content Management System

1&1

E-commerce

IONOS Email

Email Hosting

Underscore.js

Javascript Libraries

Office 365

Office Suites

Elementor

Page Builders

Bootstrap

UI Frameworks

SPARX BIOPHARMACEUTICAL CORP Email Formats	Example	Percentage
First.Last@sparxbio.com	John.Doe@sparxbio.com	100%

SPARX BIOPHARMACEUTICAL CORP Email Formats

Example

Percentage

First.Last@sparxbio.com

John.Doe@sparxbio.com

100%

Frequently Asked Questions

What is SPARX BIOPHARMACEUTICAL CORP's official website and social media links?

SPARX BIOPHARMACEUTICAL CORP's official website is sparxbio.com and has social profiles on LinkedIn.

How much revenue does SPARX BIOPHARMACEUTICAL CORP generate?

As of August 2026, SPARX BIOPHARMACEUTICAL CORP's annual revenue is estimated to be $10M - $25M.

What is SPARX BIOPHARMACEUTICAL CORP's NAICS code?

SPARX BIOPHARMACEUTICAL CORP's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does SPARX BIOPHARMACEUTICAL CORP have currently?

As of August 2026, SPARX BIOPHARMACEUTICAL CORP has approximately 18 employees across 2 continents, including North America and Asia. Key team members include Vice President, Medical And Clinical Operation: B. K. L. Explore SPARX BIOPHARMACEUTICAL CORP's employee directory with LeadIQ.

What industry does SPARX BIOPHARMACEUTICAL CORP belong to?

SPARX BIOPHARMACEUTICAL CORP operates in the Pharmaceutical Manufacturing industry.

What technology does SPARX BIOPHARMACEUTICAL CORP use?

SPARX BIOPHARMACEUTICAL CORP's tech stack includes RSS, WordPress, 1&1, IONOS Email, Underscore.js, Office 365, Elementor and Bootstrap.

What is SPARX BIOPHARMACEUTICAL CORP's email format?

SPARX BIOPHARMACEUTICAL CORP's email format typically follows the pattern of First.Last@sparxbio.com. Find more SPARX BIOPHARMACEUTICAL CORP email formats with LeadIQ.

When was SPARX BIOPHARMACEUTICAL CORP founded?

SPARX BIOPHARMACEUTICAL CORP was founded in 2018.

SPARX BIOPHARMACEUTICAL CORP

Q: How many employees does SPARX BIOPHARMACEUTICAL CORP have currently?

SPARX BIOPHARMACEUTICAL CORP has approximately 18 employees.

Q: What technology does SPARX BIOPHARMACEUTICAL CORP use?

SPARX BIOPHARMACEUTICAL CORP's tech stack includes oEmbed, RSS, IONOS, PHP, 1&1.

Q: What is SPARX BIOPHARMACEUTICAL CORP's NAICS code?

SPARX BIOPHARMACEUTICAL CORP's NAICS code is 3254 (Pharmaceutical and Medicine Manufacturing).

Pharmaceutical ManufacturingIllinois, United States11-50 Employees

SparX Biopharmaceutical Corp. is a research-based development-stage biopharmaceutical company focused on immuno-oncology, aiming to strengthen human immunity through antibody therapies. It leverages large-scale data analysis and mechanistic pharmacology, conducting in vitro and in vivo evaluations to identify novel or superior therapeutics. Based in Mount Prospect, Illinois, the company operates as a small to mid-sized enterprise with in-house cGMP facilities capable of producing clinical and commercial drug products.

SparX pursues an integrated approach to antibody drug development, combining target discovery with antibody optimization and bi-ADC strategies to improve the probability of success. In recent developments, the company attended AACR 2025 and planned to present Phase 1 clinical updates of SPX-303, a dual-checkpoint bispecific antibody. The organization aims to become an integrated, independent biopharmaceutical company.

Insights

Similar companies to SPARX BIOPHARMACEUTICAL CORP

Biogen